Corporate Compliance Programs Are Often Inadequate To Avoid Foreign Corruption Investigations, DoJ Official Says
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical companies have spent a vast amount of resources bolstering their compliance programs in the wake of government investigations of their domestic marketing practices. But their procedures may be insufficient to detect corruption and bribery abroad